Company Profile · Healthcare

Shanghai Allist Pharmaceuticals Co. Ltd. A

688578 · Shanghai

Country: China
Employees: 2,272
Website: www.allist.com.cn

Buffett Score

44/100

Weak

Financial snapshot

Market capCN¥50.21B

Revenue (TTM)CN¥6.13B

EBITDACN¥2.71B

Profit margin43.67%

ROE36.71%

P/E (TTM)18.78

Forward P/E0

EPSCN¥5.94

Dividend yield1.13%

52-week rangeCN¥78.38 – CN¥137.54

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock

No reports on this stock in your language yet.